Effect of Controlled Adverse Environment (CAE) on Tear Film Stability

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the effect of the controlled adverse environment (CAE) on Mean Break-Up Area in subjects diagnosed with Dry Eye Syndrome.

Clinical Trial Description

Single-Center, Pilot, controlled adverse environment (CAE) Study.

This is a single-center, one visit, pilot, CAE study. Dry Eye Subjects (N=30) who qualify will undergo tear film video recording, fluorescein staining, and break up time before CAE exposure and after CAE exposure.

All subjects will undergo baseline dry eye assessments including fluorescein staining, breakup time, conjunctival redness and tear film video recording. Subjects who qualify will then undergo CAE exposure for 90 minutes. At the end of CAE exposure subjects will undergo dry eye assessments again. ;

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01547936
Study type	Observational
Source	ORA, Inc.
Contact
Status	Completed
Phase	N/A
Start date	February 2012
Completion date	February 2012

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05618730` - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B	Phase 1
Completed	`NCT02254265` - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca	Phase 2/Phase 3
Completed	`NCT00883649` - Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye	N/A
Completed	`NCT00717418` - Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease	N/A
Completed	`NCT00128245` - Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca	Phase 2
Enrolling by invitation	`NCT03436576` - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye	Phase 3
Completed	`NCT04147650` - Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome	Phase 2/Phase 3
Completed	`NCT01733992` - A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease	Phase 1
Completed	`NCT00987727` - Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye	Phase 4
Completed	`NCT00788229` - Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome	Phase 2
Completed	`NCT00554879` - Acupuncture Treatment of Dry Eye	N/A
Completed	`NCT00407043` - Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis	Phase 4
Completed	`NCT00001731` - Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops	Phase 2
Recruiting	`NCT03953703` - Levocarnitine for Dry Eye in Sjogren's Syndrome	Phase 2
Withdrawn	`NCT03398018` - Repository Corticotropin Injection in Keratoconjunctivitis Sicca	Phase 4
Recruiting	`NCT02066896` - Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome	Phase 3
Completed	`NCT02139033` - A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome	Phase 4
Terminated	`NCT01213342` - Omega-3 Fatty Acid Supplements and Dry Eye	N/A
Completed	`NCT00201981` - Study of Rebamipide Eye Drops to Treat Dry Eye	Phase 3
Completed	`NCT00201955` - Study of Rebamipide Eye Drops to Treat Dry Eye	Phase 3